The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is conducting a pilot intervention study for patients diagnosed with idiopathic membranous nephropathy. The purpose of this study is to evaluate the safety and effectiveness of Rituximab plus Cyclosporine in the treatment of membranous nephropathy. There is no cost for study-related medications or tests received. The study will be conducted at the NIH Clinical Center in Bethesda, Maryland.
To participate in this study patient must:
- Be an adult at least 18 years of age
- Have a diagnosis of idiopathic membranous nephropathy
- Have had a renal biopsy within the past 24 months that shows typical changes of membranous nephropathy
Patients may not be eligible if they have:
- Received previous treatment with Rituximab
- Been treated with Cyclosporine for more than 6 months
For more information, please call toll free:
1-800-411-1222
TTY users dial 7-1-1
Se habla español
Or go online:
clinicaltrials.gov
Refer to study #09-DK-0223
Department of Health and Human Services
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases